Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Pimozide and Quinine

supplement:

Quinine

Research Papers that Mention the Interaction

The results suggest that the mechanisms by which pimozide and quinine reduce the hedonic quality of natural rewards are functionally dissimilar.
Pharmacology Biochemistry and Behavior  •  1982  |  View Paper
Several "taste reactivity" studies of dopamine and reward have concluded that pimozide suppresses the hedonic reaction patterns normally elicited by sucrose but enhances aversive reaction patterns elicited by quinine.
Pharmacology Biochemistry and Behavior  •  1997  |  View Paper
Pimozide affected ingestion of quinine in many ways, but did not affect that of sucrose solution.
The Chinese journal of physiology  •  1993  |  View Paper
Pimozide (4mg/kg, ip) also antagonised the antagonistic effect of d-amphetamine (4mg/kg, ip) on the antinociceptive effect of quinine (50mg/kg, ip).
Pimozide (4mg/kg, ip), L-sulpiride (40mg/kg, ip), SCH 23390 (0.2mg/kg, sc) and alpha-methyl-p-tyrosine (50mg/kg, ip) effectively potentiated the antinociceptive effects of quinine (50mg/kg, ip).
Progress in Neuro-Psychopharmacology and Biological Psychiatry  •  1992  |  View Paper
Pimozide (4 mg/kg, ip) significantly potentiated the protective effect of quinine (50-100 mg/kg, ip) against leptazol (80-90 mg/kg, sc)-induced seizure.
Progress in Neuro-Psychopharmacology and Biological Psychiatry  •  1990  |  View Paper
On the other hand, pimozide (0.2 mg/kg intraperitoneally), L-sulpiride (40 mg/kg intraperitoneally and SCH 23390 (0.2 mg/kg subcutaneously) potentiated the locomotor depressant effect of high doses of quinine (1-5 mg/kg) intraperitoneally).
Journal of psychopharmacology  •  1989  |  View Paper